This site uses cookies to ensure the best viewing experience for our readers.
Life Sciences Venture Fund aMoon Closes Second Fund at $660 Million

Life Sciences Venture Fund aMoon Closes Second Fund at $660 Million

The second fund will focus on mid to late-stage health companies in the domains of pharma, digital health, and medical technology

Hagar Ravet | 10:00  06.03.2019
Israel-based life sciences, healthcare, and technology venture capital firm aMoon is closing its second fund, aMoon II, at $660 million, the company announced Wednesday.

For daily updates, subscribe to our newsletter by clicking here.

 

Reuters reported the fund had $600 million in commitments in January. AMoon reported a $250 million commitment from Credit Suisse AG in May.

Digital health (illustration). Photo: Shutterstock Digital health (illustration). Photo: Shutterstock Digital health (illustration). Photo: Shutterstock

AMoon was founded in 2016 by Yair Schindel, the former CEO of an Israeli government agency in charge of pushing forward digital initiatives, and Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd. Its first fund was backed exclusively by Nacht.

Related stories

The second fund will focus on mid to late-stage health companies in the domains of pharma, digital health, and medical technology, making investments in the range of $10 million to $50 million over the next five years in 15-20 startups.

AMoon's current portfolio companies include Israel-based DayTwo Ltd., which analyzes gut microbiomes to personalize dietary recommendations, and medical analytics company Zebra Medical Vision Ltd.
share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS